|Articles|May 22, 2021

Mandatory Stop Dates, Indication Documentation Do Not Impact Length of Antibiotic Therapy

Author(s)Killian Meara

No difference was observed in any of the outcomes and there was no impact on the duration of therapy.

Shorter antibiotic therapy durations have been shown to be just as effective as longer therapy durations for many infections. Shorter durations of therapy have also resulted in fewer adverse events.

Recently, a community hospital added a computerized physician order entry (CPOE) system in the electronic health record, which requires indication, as well as the treatment duration to be documented on all antibiotic orders prior to order submission for pharmacist verification.

Investigators from the North Florida Regional Medical Center set out to determine if the implementation of this system would decrease the duration of therapy in hospitalized patients with bacterial pneumonia.

The data was presented at the 23rd Annual Making a Difference in Infectious Disease Meeting 2021 virtual sessions.

The retrospective, pretest-posttest, interrupted time series, quasi-experimental study included 138 patients, of which 56 were included in the pre-intervention group and 82 were included in the post-intervention group.

The patients were administered antibiotic therapy ≥ 48 hours for bacterial pneumonia between April 1, 2016, to May 1, 2016, and April 1, 2017, to May 1, 2017. The primary endpoint of the study was the length of therapy for antibiotics prescribed for bacterial pneumonia.

Findings from the study demonstrated that there was no difference found in the outcomes of length of hospital stay, 30-day readmission, in-hospital 30-day mortality, or incidence of in-hospital C. difficile infection.

Additionally, the median length of antibiotic therapy in the pre-intervention group was 4.4 days (IQR 2.9-5.9) and duration in the post-intervention group was 4.5 days (IQR: 3.5-5.2).

“Implementation of mandatory indication and default stop dates did not impact duration of inpatient antibiotic therapy for bacterial pneumonia patients. Requiring stop dates also did not result in harm,” the authors wrote. “Unmeasurable impacts of the required documentation includes enabling clinical evaluation of antibiotic orders, assessment for appropriateness of antibiotic selection by indication, and dose adjustments based on indication.”


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.